Olga Moshkin, Luis V. Syro, Bernd W. Scheithauer, Leon D. Ortiz, Camilo E. Fadul, Humberto Uribe, Ricardo Gonzalez, Michael Cusimano, Eva Horvath, Fabio Rotondo, Kalman Kovacs
Temozolomide (TMZ) has recently been recommended as a novel approach in the management of aggressive pituitary tumors. Herein, we present the case of a 43-year-old man with a 20-year history of silent subtype 2 pituitary corticotroph adenoma. Nine surgical resections and radiotherapy had failed to provide a cure. Morphological evaluation of the tumor revealed …